Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site. # Treadwell Therapeutics The Bold. The Curious. The Path to Better. ## Sitemaps - [XML Sitemap](https://treadwelltx.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Treadwell Expands Operations with New Local Footprint at Toronto’s University Health Network](https://treadwelltx.com/news/treadwell-expands-operations-with-new-local-footprint-at-torontos-university-health-network/) - [Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257](https://treadwelltx.com/news/treadwell-therapeutics-announces-us-fda-clearance-of-ind-application-for-phase-2-study-of-ttk-inhibitor-cfi-402257/) - [Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing](https://treadwelltx.com/news/treadwell-therapeutics-announces-the-closing-of-a-91-million-series-b-financing/) - [Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor](https://treadwelltx.com/news/treadwell-therapeutics-announces-a-presentation-at-the-2021-sabcs-annual-meeting-featuring-a-clinical-trial-update-on-cfi-402257-a-best-in-class-ttk-inhibitor/) - [Treadwell Therapeutics and University Health Network Sign Licensing Agreement for pre-clinical biologic and small molecule assets](https://treadwelltx.com/news/treadwell-therapeutics-and-university-health-network-sign-licensing-agreement-for-pre-clinical-biologic-and-small-molecule-assets/) - [Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer](https://treadwelltx.com/news/treadwell-therapeutics-announces-the-appointment-of-j-d-mowery-as-chief-operating-officer/) - [Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia](https://treadwelltx.com/news/treadwell-therapeutics-announces-fast-track-designation-granted-by-the-fda-to-cfi-400945-for-the-treatment-of-acute-myeloid-leukemia/) - [Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer](https://treadwelltx.com/news/treadwell-announces-initiation-of-patient-dosing-in-twt-203-a-phase-1b-2-study-of-ttk-inhibitor-cfi-402257-in-patients-with-er-her2-breast-cancer/) - [Treadwell Therapeutics Announces A Presentation at the 2022 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor](https://treadwelltx.com/news/treadwell-therapeutics-announces-a-presentation-at-the-2022-sitc-annual-meeting-featuring-a-clinical-trial-update-on-cfi-402411-a-first-in-class-hpk1-inhibitor/) - [Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs](https://treadwelltx.com/news/treadwell-therapeutics-announces-presentations-at-the-2022-san-antonio-breast-cancer-symposium-featuring-a-clinical-trial-update-on-the-cfi-402257-and-cfi-400945-programs/) - [Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor](https://treadwelltx.com/news/treadwell-therapeutics-announces-a-presentation-at-the-2022-sabcs-annual-meeting-featuring-a-clinical-trial-update-on-cfi-402257-a-best-in-class-ttk-inhibitor/) - [Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor](https://treadwelltx.com/news/treadwell-therapeutics-announces-a-presentation-at-the-2022-ash-annual-meeting-featuring-a-clinical-trial-update-on-cfi-400945-an-oral-plk4-inhibitor/) - [Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer](https://treadwelltx.com/news/2023/treadwell-therapeutics-announces-fast-track-designation-granted-by-the-fda-to-cfi-402257-for-the-treatment-of-er-her2-breast-cancer/) - [Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer](https://treadwelltx.com/news/2023/treadwell-therapeutics-announces-the-appointment-of-roger-sidhu-m-d-as-chief-medical-officer/) - [Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)](https://treadwelltx.com/news/treadwell-announces-initiation-of-new-clinical-trial-of-cfi-400945-in-patients-with-metastatic-castrate-resistant-prostate-cancer-mcrpc/) - [Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945](https://treadwelltx.com/news/treadwell-announces-two-presentations-at-the-2020-ash-annual-meeting-featuring-clinical-trial-updates-on-lead-product-candidate-cfi-400945/) - [Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia](https://treadwelltx.com/news/initiation-of-patient-dosing-in-twt-202-a-phase-1b-2-study-of-plk4-inhibitor-cfi-400945-in-patients-with-leukemia/) - [Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company](https://treadwelltx.com/news/treadwell-therapeutics-announces-acquisition-of-tcryption-inc-a-novel-tcr-based-t-cell-therapy-company-and-tio-bioventures-portfolio-company/) - [Treadwell Therapeutics Announces a Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor](https://treadwelltx.com/news/treadwell-therapeutics-announces-a-presentation-at-the-2021-sitc-annual-meeting-featuring-a-clinical-trial-update-on-cfi-402411-a-first-in-class-hpk1-inhibitor/) - [Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia](https://treadwelltx.com/news/treadwell-announces-ocifisertib-a-first-in-class-plk4-inhibitor-has-received-orphan-designation-from-u-s-fda-for-the-treatment-of-acute-myeloid-leukemia/) - [Treadwell Announces the Formation and Members of Scientific Advisory Board](https://treadwelltx.com/news/treadwell-announces-the-formation-and-members-of-scientific-advisory-board/) - [Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting](https://treadwelltx.com/news/2023/treadwell-therapeutics-announces-a-presentation-at-the-2023-ash-annual-meeting-and-advisory-board-meeting/) - [Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions](https://treadwelltx.com/news/2023/treadwell-announces-strategic-pipeline-prioritization-and-leadership-transitions/) ## Pages - [Home](https://treadwelltx.com/) - [Careers](https://treadwelltx.com/careers/) - [Science](https://treadwelltx.com/science/) - [Terms of Use](https://treadwelltx.com/terms-of-use/) - [Page Template](https://treadwelltx.com/page-template/) - [Menu](https://treadwelltx.com/menu/) - [Contact](https://treadwelltx.com/contact/) - [About](https://treadwelltx.com/about/) - [Pipeline](https://treadwelltx.com/pipeline/) - [News](https://treadwelltx.com/news/) ## Portfolio Items - [Mark R. Bray, PhD](https://treadwelltx.com/team/mark-r-bray-phd/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor-6/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor-5/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor-4/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor-3/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor-2/) - [Lorem ipsum dolor](https://treadwelltx.com/team/lorem-ipsum-dolor/) - [Antoni Ribas, M.D., Ph.D.](https://treadwelltx.com/team/antoni-ribas-m-d-ph-d/) - [Carl June, M.D.](https://treadwelltx.com/team/carl-june-m-d/) - [Pasi A. Jänne, M.D., Ph.D.](https://treadwelltx.com/team/pasi-a-janne-m-d-ph-d/) - [S. Gail Eckhardt](https://treadwelltx.com/team/s-gail-eckhardt/) - [Lillian L Siu, M.D., FRCPC](https://treadwelltx.com/team/lillian-l-siu-m-d-frcpc/) - [Patricia LoRusso](https://treadwelltx.com/team/patricia-lorusso/) - [Tak Wah Mak, PhD](https://treadwelltx.com/team/tak-wah-mak/) - [Tak Wah Mak, PhD](https://treadwelltx.com/team/tak-wah-mak-phd/) ## Categories - [news](https://treadwelltx.com/category/news/) - [2021](https://treadwelltx.com/category/news/2021/) - [2022](https://treadwelltx.com/category/news/2022/) - [2020](https://treadwelltx.com/category/news/2020/) - [2023](https://treadwelltx.com/category/news/2023/) - [2024](https://treadwelltx.com/category/news/2024/) ## Portfolio Categories - [Leadership](https://treadwelltx.com/portfolio_entries/leadership/) - [BOD](https://treadwelltx.com/portfolio_entries/bod/) - [SAB](https://treadwelltx.com/portfolio_entries/sab/)